Recently, Haisen Biopharmaceuticals announced that its overseas affiliated company, Haisen Biopharmaceuticals (Asia), has successfully completed the Market Authorization Transfers (MAT) for 11 products in various regions of Asia-Pacific such as Malaysia, Singapore, the Philippines, and Hong Kong during the first half of this year, accelerating the construction of a global commercial ecosystem that radiates across the Asia-Pacific, bringing quality products and solutions to more patients.
The products that have obtained MAT approval in various Asia-Pacific regions mainly cover chronic disease areas such as cardiovascular diseases and diabetes, including Actos®, Actosmet®, Blopress®, Blopress Plus®, Nesina®, Nesinamet®, Ubretid®, Unisia®, Albothyl®, Edarbi®, Oseni®, and others. Leveraging its mature experience system in registration applications, production transfers, and marketing in the Asia-Pacific region, the company will provide efficient and professional services to help more global biopharmaceutical partners accelerate localization operations and commercialization on the ground, and realize the Asia-Pacific development strategy as soon as possible.
The rapid achievement of MAT transfers across multiple regions demonstrates the company’s strength in aligning with international standards in registration
